Trial Profile
A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Trial of Maintenance Treatment With BGB-290 Versus Placebo in Patients With Platinum-sensitive Recurrent Ovarian Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 22 Aug 2022
Price :
$35
*
At a glance
- Drugs Pamiparib (Primary)
- Indications Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Registrational; Therapeutic Use
- Sponsors BeiGene
- 18 Aug 2022 Planned primary completion date changed from 30 Jun 2022 to 30 Jun 2025.
- 25 Feb 2022 According to a BeiGene media release, topline results are expected in the first half of 2022.
- 22 Jun 2021 Planned End Date changed from 30 Apr 2021 to 30 Jun 2026.